REYATAZ

Product NDC: 0003-3622
11-digit product format: 000033622
Labeler code: 0003
Product ID: 0003-3622_510c2d51-4943-401c-a008-ea22f61c6938
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: ATAZANAVIR
Dosage form: CAPSULE, GELATIN COATED
Route: ORAL
Labeler: E.R. Squibb & Sons, L.L.C.
Application: NDA021567
Marketing category: NDA
Marketing start: 2003-06-24
Substance: ATAZANAVIR SULFATE
Active strength: 300 mg/1
Pharmacologic classes: Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inhibitors [MoA], UGT1A1 Inhibitors [MoA]
NDC exclude flag: No
Listing certified through: 2026-12-31
Current FDA listing: Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 4 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N021567-001	REYATAZ	ATAZANAVIR SULFATE	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20
N021567-002	REYATAZ	ATAZANAVIR SULFATE	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20
N021567-003	REYATAZ	ATAZANAVIR SULFATE	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20
N021567-004	REYATAZ	ATAZANAVIR SULFATE	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-product	TE code
N021567-003	AB
N021567-004	AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 5 · 164 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	RLD / RS	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N021567-001	REYATAZ	EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N021567-002	REYATAZ	EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE / ORAL		RLD	2003-06-20	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N021567-003	REYATAZ	EQ 200MG BASE	CAPSULE / ORAL	AB	RLD	2003-06-20	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N021567-004	REYATAZ	EQ 300MG BASE	CAPSULE / ORAL	AB	RLD, RS	2006-10-16	`d06236e962d9…`

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 94 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N021567-003	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021567-004	AB	1	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021567-003	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021567-004	AB	1	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N021567-003	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N021567-004	AB	1	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021567-003	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021567-004	AB	1	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021567-003	AB	1	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021567-004	AB	1	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021567-003	AB	1	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021567-004	AB	1	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021567-003	AB	1	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021567-004	AB	1	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021567-003	AB	1	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021567-004	AB	1	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021567-003	AB	1	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021567-004	AB	1	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N021567-003	AB	1	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N021567-004	AB	1	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N021567-003	AB	1	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N021567-004	AB	1	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N021567-003	AB	1	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N021567-004	AB	1	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N021567-003	AB	1	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N021567-004	AB	1	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N021567-003	AB	1	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N021567-004	AB	1	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N021567-003	AB	1	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N021567-004	AB	1	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N021567-002	AB	1	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N021567-003	AB	1	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N021567-004	AB	1	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N021567-002	AB	1	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N021567-003	AB	1	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N021567-004	AB	1	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N021567-002	AB	1	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021567-003	AB	1	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021567-004	AB	1	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	N021567-002	AB	1	`bb7c543d1eb4…`

Observed Orange Book patent history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Coverage / status	Source SHA-256
2019-12-13 00:20 UTC	2019-12	N021567-001	6087383*PED	2019-06-21	Pediatric extension	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021567-002	6087383*PED	2019-06-21	Pediatric extension	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021567-003	6087383*PED	2019-06-21	Pediatric extension	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021567-004	6087383*PED	2019-06-21	Pediatric extension	`74a2ff9319b5…`
2019-12-14 00:12 UTC	2019-12	N021567-001	6087383*PED	2019-06-21	Pediatric extension	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N021567-002	6087383*PED	2019-06-21	Pediatric extension	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N021567-003	6087383*PED	2019-06-21	Pediatric extension	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N021567-004	6087383*PED	2019-06-21	Pediatric extension	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N021567-001	6087383*PED	2019-06-21	Pediatric extension	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N021567-002	6087383*PED	2019-06-21	Pediatric extension	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N021567-003	6087383*PED	2019-06-21	Pediatric extension	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N021567-004	6087383*PED	2019-06-21	Pediatric extension	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N021567-001	6087383*PED	2019-06-21	Pediatric extension	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N021567-002	6087383*PED	2019-06-21	Pediatric extension	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N021567-003	6087383*PED	2019-06-21	Pediatric extension	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N021567-004	6087383*PED	2019-06-21	Pediatric extension	`ea99ee380514…`

Additional Listing Data#

Finished product: Yes
Brand name base: REYATAZ
Listing expiration: 2026-12-31

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
ATAZANAVIR SULFATE	300 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
4MT4VIE29P	Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 8 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
402093	Internal RxNorm lookup
402094	Internal RxNorm lookup
402246	Internal RxNorm lookup
402247	Internal RxNorm lookup
664741	Internal RxNorm lookup
664743	Internal RxNorm lookup
1598985	Internal RxNorm lookup
1598989	Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
165cff62-b284-4a27-a65d-9ec8a5bfcdd8	Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
6c13b22c-b3ba-4127-b768-0132dd5ab0d1	Product name	1	20230829
7bc938bd-f454-36ec-72ed-9ef05424b276	Product name	8	20221117
7792dadb-52b6-46b6-8fdf-80b1171065b5	Product name	1	20180810
248d7995-abf1-4569-b3c6-f9ebc230e8ef	Product name	1	20150323

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
0003-3622-12	REYATAZ	30 in 1 BOTTLE, PLASTIC	CAPSULE, GELATIN COATED	30		37

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
0003-3622-12	EA - Each	0003-3622	193b4b9b-ca46-40f9-ac8f-da94c02a935e	1	2012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
ATAZANAVIR SULFATE	ACTIVE INGREDIENT	4MT4VIE29P	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
ATAZANAVIR	ACTIVE MOIETY	QZU4H47A3S	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
ALCOHOL	INACTIVE INGREDIENT	3K9958V90M	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
AMMONIA	INACTIVE INGREDIENT	5138Q19F1X	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
ASPARTAME	INACTIVE INGREDIENT	Z0H242BBR1	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
BUTYL ALCOHOL	INACTIVE INGREDIENT	8PJ61P6TS3	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
CROSPOVIDONE	INACTIVE INGREDIENT	68401960MK	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
FD&C BLUE NO. 2	INACTIVE INGREDIENT	L06K8R7DQK	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
FERROSOFERRIC OXIDE	INACTIVE INGREDIENT	XM0M87F357	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
GELATIN	INACTIVE INGREDIENT	2G86QN327L	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
ISOPROPYL ALCOHOL	INACTIVE INGREDIENT	ND2M416302	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
LACTOSE MONOHYDRATE	INACTIVE INGREDIENT	EWQ57Q8I5X	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
PROPYLENE GLYCOL	INACTIVE INGREDIENT	6DC9Q167V3	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
SHELLAC	INACTIVE INGREDIENT	46N107B71O	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
SUCROSE	INACTIVE INGREDIENT	C151H8M554	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
TITANIUM DIOXIDE	INACTIVE INGREDIENT	15FIX9V2JP	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	22
ATAZANAVIR SULFATE	ACTIVE INGREDIENT	4MT4VIE29P	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
ATAZANAVIR	ACTIVE MOIETY	QZU4H47A3S	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
ALCOHOL	INACTIVE INGREDIENT	3K9958V90M	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
AMMONIA	INACTIVE INGREDIENT	5138Q19F1X	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
BUTYL ALCOHOL	INACTIVE INGREDIENT	8PJ61P6TS3	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
CROSPOVIDONE	INACTIVE INGREDIENT	68401960MK	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
FD&C BLUE NO. 2	INACTIVE INGREDIENT	L06K8R7DQK	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
FERROSOFERRIC OXIDE	INACTIVE INGREDIENT	XM0M87F357	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
GELATIN	INACTIVE INGREDIENT	2G86QN327L	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
ISOPROPYL ALCOHOL	INACTIVE INGREDIENT	ND2M416302	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
LACTOSE MONOHYDRATE	INACTIVE INGREDIENT	EWQ57Q8I5X	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
PROPYLENE GLYCOL	INACTIVE INGREDIENT	6DC9Q167V3	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
SHELLAC	INACTIVE INGREDIENT	46N107B71O	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2
TITANIUM DIOXIDE	INACTIVE INGREDIENT	15FIX9V2JP	REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [PHYSICIANS TOTAL CARE, INC.]	2

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
0003-3622	REYATAZ (ATAZANAVIR) CAPSULE, GELATIN COATED REYATAZ (ATAZANAVIR) POWDER [E.R. SQUIBB & SONS, L.L.C.]	36	Current NDC, Legacy NDC, 1 package rows	20241220_165cff62-b284-4a27-a65d-9ec8a5bfcdd8.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
REYATAZ	ATAZANAVIR	E.R. Squibb & Sons, L.L.C.	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	2024-12-05	Warnings, Adverse reactions	Exact identifier application applno (NDA): 021567 application number: NDA021567 ndc (product): 0003-3622

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
4MT4VIE29P	ATAZANAVIR SULFATE	229975-97-7	ATAZANAVIR SULFATE
QZU4H47A3S	ATAZANAVIR	198904-31-3	ATAZANAVIR

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
1598985	atazanavir 50 MG Oral Powder	PSN	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402246	atazanavir sulfate 150 MG Oral Capsule	PSN	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402247	atazanavir sulfate 200 MG Oral Capsule	PSN	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
664741	atazanavir sulfate 300 MG Oral Capsule	PSN	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402094	Reyataz 150 MG Oral Capsule	PSN	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402093	Reyataz 200 MG Oral Capsule	PSN	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
664743	Reyataz 300 MG Oral Capsule	PSN	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
1598989	Reyataz 50 MG Oral Powder	PSN	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402094	atazanavir 150 MG Oral Capsule [Reyataz]	SBD	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402093	atazanavir 200 MG Oral Capsule [Reyataz]	SBD	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
664743	atazanavir 300 MG Oral Capsule [Reyataz]	SBD	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
1598989	atazanavir 50 MG Oral Powder [Reyataz]	SBD	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402246	atazanavir 150 MG Oral Capsule	SCD	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402247	atazanavir 200 MG Oral Capsule	SCD	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
664741	atazanavir 300 MG Oral Capsule	SCD	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
1598985	atazanavir 50 MG Oral Powder	SCD	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
1598989	atazanavir (as atazanavir sulfate 56.9 MG) Oral Powder [Reyataz]	SY	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402246	atazanavir 150 MG (as atazanavir sulfate 170.8 MG) Oral Capsule	SY	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402247	atazanavir 200 MG (as atazanavir sulfate 227.8 MG) Oral Capsule	SY	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
664741	atazanavir 300 MG (as atazanavir sulfate 341.69 MG) Oral Capsule	SY	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
1598985	atazanavir 50 MG (as atazanavir sulfate 56.9 MG) Oral Powder	SY	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402094	Reyataz 150 MG Oral Capsule	SY	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
402093	Reyataz 200 MG Oral Capsule	SY	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
664743	Reyataz 300 MG Oral Capsule	SY	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
1598989	Reyataz 50 MG per packet Oral Powder	SY	165cff62-b284-4a27-a65d-9ec8a5bfcdd8	37
664741	atazanavir sulfate 300 MG Oral Capsule	PSN	4f424439-c809-22fc-e054-00144ff8d46c	3
664741	atazanavir 300 MG Oral Capsule	SCD	4f424439-c809-22fc-e054-00144ff8d46c	3
664741	atazanavir 300 MG (as atazanavir sulfate 341.69 MG) Oral Capsule	SY	4f424439-c809-22fc-e054-00144ff8d46c	3
402246	atazanavir sulfate 150 MG Oral Capsule	PSN	025876b6-f031-43ea-967a-b1d95b4685a6	2
402247	atazanavir sulfate 200 MG Oral Capsule	PSN	025876b6-f031-43ea-967a-b1d95b4685a6	2
664741	atazanavir sulfate 300 MG Oral Capsule	PSN	025876b6-f031-43ea-967a-b1d95b4685a6	2
402094	Reyataz 150 MG Oral Capsule	PSN	025876b6-f031-43ea-967a-b1d95b4685a6	2
402093	Reyataz 200 MG Oral Capsule	PSN	025876b6-f031-43ea-967a-b1d95b4685a6	2
664743	Reyataz 300 MG Oral Capsule	PSN	025876b6-f031-43ea-967a-b1d95b4685a6	2
402094	atazanavir 150 MG Oral Capsule [Reyataz]	SBD	025876b6-f031-43ea-967a-b1d95b4685a6	2
402093	atazanavir 200 MG Oral Capsule [Reyataz]	SBD	025876b6-f031-43ea-967a-b1d95b4685a6	2
664743	atazanavir 300 MG Oral Capsule [Reyataz]	SBD	025876b6-f031-43ea-967a-b1d95b4685a6	2
402246	atazanavir 150 MG Oral Capsule	SCD	025876b6-f031-43ea-967a-b1d95b4685a6	2
402247	atazanavir 200 MG Oral Capsule	SCD	025876b6-f031-43ea-967a-b1d95b4685a6	2
664741	atazanavir 300 MG Oral Capsule	SCD	025876b6-f031-43ea-967a-b1d95b4685a6	2
402246	atazanavir 150 MG (as atazanavir sulfate 170.8 MG) Oral Capsule	SY	025876b6-f031-43ea-967a-b1d95b4685a6	2
402247	atazanavir 200 MG (as atazanavir sulfate 227.8 MG) Oral Capsule	SY	025876b6-f031-43ea-967a-b1d95b4685a6	2
664741	atazanavir 300 MG (as atazanavir sulfate 341.69 MG) Oral Capsule	SY	025876b6-f031-43ea-967a-b1d95b4685a6	2
402094	Reyataz 150 MG Oral Capsule	SY	025876b6-f031-43ea-967a-b1d95b4685a6	2
402093	Reyataz 200 MG Oral Capsule	SY	025876b6-f031-43ea-967a-b1d95b4685a6	2
664743	Reyataz 300 MG Oral Capsule	SY	025876b6-f031-43ea-967a-b1d95b4685a6	2

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Marketing start	Marketing end	Sample	Exclude flag	Status
0003-3622-12	00003362212	30 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3622-12)	2003-06-24	0000-00-00	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
REYATAZ	E.R. Squibb & Sons, L.L.C.	2024-12-05	HUMAN PRESCRIPTION DRUG LABEL	37
REYATAZ - RedPharm Drug, Inc.	RedPharm Drug, Inc.	2022-01-20	HUMAN PRESCRIPTION DRUG LABEL	3
REYATAZ	REMEDYREPACK INC.	2020-04-06	HUMAN PRESCRIPTION DRUG LABEL	7
REYATAZ	A-S Medication Solutions	2017-11-08	HUMAN PRESCRIPTION DRUG LABEL	6
REYATAZ	Physicians Total Care, Inc.	2012-02-17	HUMAN PRESCRIPTION DRUG LABEL	2